Announcements Trials
Browse Landscape

Phase

Phase 2 16Phase 1 3Phase 3 2Phase 2/3 2Phase 1/2 2

Status

Unknown 2Completed 2Terminated 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Gynecologic 1Gastrointestinal 1

Conditions

Uterine Cervical Neoplasms 1Colorectal Neoplasms 1

Interventions

Cyclophosphamide 142Gemcitabine 129Paclitaxel 125Radiotherapy 119Carboplatin 112Cisplatin 111pembrolizumab 110Nivolumab 106Docetaxel 90Rituximab 86Lenalidomide 77Dexamethasone 76Cytarabine 69Bevacizumab 64Fluorouracil 63Etoposide 63Oxaliplatin 62Filgrastim 59Peripheral Blood Stem Cell Transplantation 58Everolimus 58Capecitabine 58fludarabine phosphate 57Doxorubicin 56Temozolomide 55Prednisone 54Irinotecan 53Cetuximab 50fludarabine 48Ipilimumab 48Erlotinib Hydrochloride 48

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 1/2 × Completed × nimotuzumab × Clear all
NCT05278728 2025-02-07

Phase IIa Study of Nimotuzumab to Treat Colorectal Cancer

Biotech Pharmaceutical Co., Ltd.

Phase 1/2 Completed
31 enrolled
Gastrointestinal

Colorectal Neoplasms

NCT02095119 2015-04-14

A Monoclonal Antibody, Nimotuzumab, as Treatment for Recurrent or Metastatic Cervical Cancer

National Institute of Cancerología

Phase 1/2 Completed
15 enrolled
Gynecologic

Uterine Cervical Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡